Incruse Ellipta 55 micrograms inhalation powder

Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE

THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B+)